They died saving others from Covid. Will anyone count them?
15 minutes to read
By: Andrew Jacobs
Medical workers are called heroes. But there hasn t been a national reckoning over the many thousands lost to Covid. Here are a few of the people who gave their lives while on the front lines of the pandemic.
Dr. Claire Rezba is exhausted from counting the dead.
An anaesthesiologist in Virginia, Rezba, 41, has spent the past year running a Twitter feed that memorialises American health care workers who have died of Covid-19. So far, she has published more than 2,500 tributes to the doctors, emergency room nurses, respiratory therapists and mental health counsellors cut down in their prime. Although she knows there are at least a thousand other deaths that remain unrecognised, Rezba plans to discontinue the project at the end of March.
BASILICA Technique Prevents TAVR-Related Coronary Obstruction medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
California punishes hospitals for vaccinating teachers.
Washington vaccinates all seniors â and warns older Oregonians against trying to sneak north for an early shot.
Governors around the country have issued edicts during the COVID-19 crisis that often conflict with neighboring states, creating a national patchwork of do s and don ts. States are all over the place, said Dr. Arthur Caplan, director of New York University Langone s Division of Medical Ethics. It s rarely clear why restrictions are expanded or removed. Criteria are modified without explanation.
The COVID-19 pandemic is the greatest public health crisis in a century, made all the more difficult by strict adherence to a geographical fiction: The United States is 50 distinct states.Â
Jan 28, 2021 10:45pm Johnson & Johnson is seeking a nod for amivantamab as a second-line treatment for lung cancer patients with a rare EGFR mutation, but the company is already working on moving the candidate into the front-line setting. (Janssen)
Johnson & Johnson’s EGFR-MET bispecific antibody is padding its case ahead of a potential FDA nod. The drug shrank tumors in 40% of lung cancer patients with a rare EGFR mutation and curbed tumor growth in nearly three-quarters of patients.
The phase 2 data, presented virtually at the World Conference on Lung Cancer (WCLC), come from 81 patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The patients’ cancer had spread beyond the lungs or couldn’t be treated with surgery and had gotten worse despite taking platinum chemotherapy.
Janssen: New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
FOR EU TRADE AND MEDICAL MEDIA ONLY Not for distribution in the UK and Benelux
The Janssen Pharmaceutical Companies of Johnson Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.
1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings showed robust activity and durable responses with a tolerable and manageable safety profile (Abstract #3031) in patients with NSCL